The medical community is abuzz with anticipation surrounding retatrutide, a new dual GIP and GLP-1 agonist that’s demonstrating significant efficacy in clinical trials for treating obesity. Unlike some available weight loss treatments, retatrutide appears to deliver a greater substantial loss in body weight and improve metabolic health, particula